News | Ventricular Assist Devices (VAD) | March 08, 2017

Alabama Man Sees Quality of Life Improve After LVAD Surgery

Former firefighter received left ventricular assist device as bridge-to-transplant therapy at University of Alabama at Birmingham

James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham

March 8, 2017 —  Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a device that can improve quality of life while waiting for a heart transplant.

A left ventricular assist device (LVAD) is a mechanical heart pump used for patients who have reached end-stage congestive heart failure. Once the LVAD is surgically implanted, the battery-operated, mechanical pump helps the circulating function of the left ventricle — the main pumping chamber of the heart — pump blood to the rest of the body.

“This is amazing, lifesaving technology,” said Salpy Pamboukian, M.D., director of the Mechanical Circulatory Support Device Program at the University of Alabama at Birmingham. “Our patients have excellent quality of life after these procedures.”

LVADs can be used as bridge-to-transplant therapy. This is a lifesaving therapy for patients awaiting a heart transplant. Patients use the LVAD until a heart becomes available. In some cases, the LVAD is able to restore the failing heart, eliminating the need for a transplant.

The LVAD can also be used as a destination therapy: Some patients are not candidates for heart transplants. In this case, patients can receive long-term treatment using an LVAD, which can prolong and improve patients’ lives.

James Ward, of Dothan, Ala., received his LVAD device in 2016 and is a bridge-to-transplant patient. After going through the procedure, he said he has not felt this good for a long time.

“I never thought I could feel this good,” Ward said. “I’m way better than what my normal was.”

Ward, a former firefighter for the city of Dothan for nearly 20 years, was forced to retire after he was diagnosed with congestive heart failure in 2001. While he did not feel like himself for years, the LVAD device he received at UAB has provided him reassurance about his future, which includes spending time with his two children and four grandchildren.

“At some points before I retired, I couldn’t walk from my vehicle to my office,” he said. “Now I can walk. It’s a second chance.”

Patients who receive the LVAD are required to wear a battery and control system pack around the waist. The LVAD pulls blood from the left ventricle into a pump. The pump is placed in the upper part of the abdomen, while another tube attached to the pump is brought out of the abdominal wall to the outside of the body and attached to the pump’s battery and control system.

While it is a lifestyle change, the end result is worth it. Pamboukian said good social support is key to recovery.

“I have to have a caretaker with me most of the time, and I can’t drive; but people need to be aware of these devices because they can save lives, and that’s worth it,” Ward said.

While technology keeps advancing, Pamboukian noted that UAB is the only center in Alabama implanting LVAD devices in patients.

“We encourage patients to research their condition,” she said. “A lot of times, people don’t understand what their options are. Waiting times for heart transplants vary for each person, and people can have excellent lives while they are on this device.”

For more information: www.uab.edu

Related Content

New Target for Treating Heart Failure Identified by Penn Medicine Researchers

Microtubules in heart cells from a healthy patient (left) and from a patient with heart failure. The dense network of detyrosinated microtubules impedes the motion of the failing heart cell during the heart beat. Credit: Ben Prosser lab, Perelman School of Medicine, University of Pennsylvania

News | Heart Failure | June 25, 2018
New research finds changes in cellular struts called microtubules (MT) can affect the stiffness of diseased human heart...
Gencaro Does Not Reduce Atrial Fibrillation Risk in Heart Failure Patients
News | Heart Failure | May 30, 2018
Data from the GENETIC-AF trial was presented in a “Late Breaking Clinical Trials” oral presentation at the European...
Cardiac Contractility Modulation Safe and Effective as Heart Failure Treatment

Image courtesy of Impulse Dynamics

News | Heart Failure | May 18, 2018
In a new study, cardiac contractility modulation (CCM) therapy was confirmed to significantly improve exercise...
V-Wave Closes $70M Financing to Support Pivotal Study of Heart Failure Therapy
News | Heart Failure | May 16, 2018
Israel-based V-Wave Ltd. recently closed a $70 million Series C financing for its proprietary, minimally invasive...
News | Heart Failure | May 14, 2018
Ancora Heart Inc. announced the expansion of the company’s U.S. feasibility study to evaluate the investigational...
Protein Clumping May Contribute to Heart Failure Development

A PET scan detects clumping proteins in rat hearts (top). The enlarged heart (right) is one with heart failure. Other PET scans showing blood flow in the rat hearts (bottom) show that the protein clumps aren't due to circulation problems. Image courtesy of Circulation Research, May 11, 2018.

News | Heart Failure | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Minnesota Living With Heart Failure Questionnaire Qualified for FDA Medical Device Development Tools Program

The CORolla device from Israel-based CorAssist is one example of new devices being manufactured and tested to treat heart failure. The efficacy of this and other new devices under development can now be assessed with the Minnesota Living With Heart Failure Questionnaire. 

Technology | Heart Failure | May 07, 2018
The U.S. Food and Drug Administration (FDA) has qualified the Minnesota Living with Heart Failure Questionnaire from...
Nation's First Heart Failure and Arrhythmia Center Opening in Ohio

Image courtesy of The Ohio State University

News | Heart Failure | April 04, 2018
The Ohio State University Wexner Medical Center will establish the nation’s first center dedicated to treating those...
Abbott Initiates GUIDE-HF Trial for Improved Outcomes With CardioMEMS Monitor
News | Heart Failure | March 29, 2018
Abbott announced the company has initiated the landmark GUIDE-HF clinical trial using the CardioMEMS HF System. The...
Videos | Heart Failure | March 23, 2018
David Lanfear M.D., FACC, head of advanced heart failure and cardiac transplantation, Henry Ford Hospital, Detroit, d
Overlay Init